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Objectives: Payments for Performance (P4P) schemes are commonly used in 
many OECD countries in order to incite physicians to improve both quality and 
efficiency of prescribing. In France, a set of 29 indicators has been selected as the 
P4P perimeter by National Public Health Insurance. Each indicator provides useful 
information of GPs’ performance, but it is not that easy to combine them all at 
the same time in order to provide a synthetic view of GPs’ performance. Instead, 
some of these indicators can be grouped together according to a therapeutic ration-
ale (diabetes indicators, high blood pressure indicators) or an efficiency rationale 
(multiple-sourced drug prescribing). Data Envelopment Analysis (DEA) can be used 
to calculate an aggregated score for each GP and for each dimension (therapeutic or 
efficiency). MethOds: Database used in this study were taken from the IMS-Health 
Disease Analyzer (DA) database. It contains information on pharmaceutical pre-
scriptions administered by 693 French General Practitioners and related diagnoses. 
Quality and efficiency indicators are calculated both inside and outside P4P perim-
eter. Indicators reflecting efficiency are considered separately from those reflecting 
quality and the latter are grouped according to therapeutic rationale (diabetes, high 
blood pressure). Data Envelopment Analysis (DEA) is used to produce performance 
scores while aggregating several efficiency or quality scores and neutralizing at the 
same time each GP’s characteristics. Results: DEA scores are calculated on each 
dimension (quality or efficiency) and for each GP. Comparing the scores on each 
dimension enables to better understand if GPs’ are faced with a trade-off between 
these two Objectives. cOnclusiOns: Results from this analysis may have implica-
tions for public policy design. A better understanding of GPs’ strategies relatively 
to P4P schemes could enable to adapt incentives in order to improve the system.
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Objectives: Neonates are among special population group who are more 
susceptible to nosocomial infections due to underdeveloped immunity level at 
their age (0-28 days of life) and it is a common practice of administering anti-
biotics, pending bacterial culture results, to sick neonates and to neonates who 
are more prone to develop infectious diseases; which in turn is gradually pro-
gressing towards a global problem of multidrug antibiotic resistance in Neonatal 
Intensive Care Units. Objective of the present study was to study prescribing pat-
terns of antibiotics in hospitalized neonates, and to assess duration of therapy, 
antibiotic regimen and outcome of therapy. MethOds: All neonates prescribed 
with antibiotics during 6 months period from November 2014 to April 2014 were 
selected. A prospective observational study was carried on selected cases by 
using sources of data such as patient treatment charts, progress sheet, labora-
tory investigation reports, and patient discharge summary; collected datas were 
reported in case record forms. Data analysis was done with SPSS (18.0), Microsoft 
Excel (2010). Results: Of the total of 404 admitted neonates, 30% (n = 122) were 
prescribed with antibiotics; among which 76 (62.3%) males and 46 (37.7%) were 
females. Among n= 122 cases, 71 (58.2%) empirically and 51 (41.8%) were pre-
scribed in indication of infections. Most commonly prescribed antibiotic class were 
Aminoglycoside (97.54%), broad spectrum penicillin (66.39%), extended spectrum 
penicillin (28.68%), 2ndgeneration cephalosporin (17.21%). Empirical use of ampi-
cillin and amikacin were most frequently encountered. Our study showed that 
Dual antibiotic regimen produced a better outcome (50%) than single/triple/more 
antibiotic regimen. cOnclusiOns: The broader outcome of this study would be 
the potential utility of this data in designing strategies both at level of physicians 
and administrators for rational prescribing and policy decisions respectively; so 
that a continuous surveillance for rational use of antibiotics and strategy of anti-
biotic cycling can provide some better answers for difficulties coming across in 
management of neonatal infections.
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Objectives: Payments for Performance (P4P) schemes are commonly used 
in many OECD countries in order to incite physicians to improve both quality 
and efficiency of prescribing. In France, a set of 29 indicators has been selected 
as the P4P perimeter by National Public Health Insurance. P4P schemes may 
induce undesirable behaviors from GPs leading to a decrease both in quality and 
efficiency outside the P4P perimeter (De Pouvourville, 2013). On the contrary, 
other studies (Campbell et al., 2009) tend to show that respecting P4P targets 
may imply a virtuous effect outside P4P. MethOds: Database used in this study 
were taken from the IMS-Health Disease Analyzer (DA) database. It contains 
information on pharmaceutical prescriptions administered by 693 French General 
Practitioners and related diagnoses. Quality and efficiency indicators are calcu-
lated both inside and outside P4P perimeter. In a first step, each category –quality 
or efficiency- is considered separately. We calculate an aggregated score for each 
category, by averaging indicators pertaining to it. In a second step, each indicator 
outside the P4P perimeter is regressed on quality or efficiency aggregated scores, 
controlling for other characteristics of the physician. Results: At first sight, 
there is no obvious link between quality and efficiency scores inside and outside 
P4P perimeter. As a matter of fact, descriptive statistics, correlation analysis and 
Principal Component Analysis do not show any straightforward relation. All these 
first results call for further analyses. cOnclusiOns: Results from this analysis 
may have implications for public policy design. If respecting P4P targets imply a 
virtuous effect outside P4P, there is no need to extend the P4P perimeter. If not, 
regulatory agency has to increase the number of indicators in order to improve 
quality and efficiency.
NSAIDs present in household drug supplies, and address the issue of possible inad-
equate use. MethOds: This was an observational, cross-sectional study of drug 
storage and self-medication practice in households in the city of Novi Sad, Serbia 
over the 8 months period. Study consisted of personal insight into the drug inven-
tory, and drugs were classified according the Anatomical Therapeutic Chemical 
(ATC) classification system. Results: Out of 383 surveyed households, 280/383 
(73%) households held at least one box of NSAID in their home-pharmacy and a 
total of 473 packages of NSAID have been inventored. Most commonly encoun-
tered NSAIDs were ibuprofen (52.64%), diclofenac (31.92%), nimesulide (8.03%) and 
meloxicam (3.38%). Other NSAIDs accounted for less than 4% altogether. Over 70% 
of all NSAIDs present have been bought without prescription. Majority of ibuprfoen 
(91.3%) and diclofenac (65.74%) were obtained without a prescription even though 
in Serbia all NSAIDs (except ibuprofen 200mg) are prescription only medication 
(POM). According to European Medicine Agency, ibuprofen is classified as OTC, 
but diclofenac is strictly POM. Large amount of diclofenac used without consult-
ing a physician presents a serious issue. Nimesulide and meloxicam were almost 
exclusively bought with prescription (> 80%). cOnclusiOns: NSAIDs were pre-
sent in most of Serbian home-pharmacies and were usually bought without pre-
scription. This present a serious problem, especially for unsupervized diclofenac 
use. Financial Sources: This work was supported by the Ministry of Science and 
Technological Development, Republic of Serbia, project No. 41012.
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Objectives: to investigate changing of Candida species (C. spp) distribution and 
expenditure for antimicrobial drugs in the intensive care unit (ICU). MethOds: 
From 1.01.11 to 30.07.13 there were 200 patients with Candida spp positive samples 
in the ICU. We followed up antifungal drugs susceptibility of different C. spp. and 
evaluated expenditure for antifungal drugs. Results: C spp was detected in 200 
patients (12,2% of ICU microbiota). In 2011: 47 (19,3%); in 2012: 50 (9,3%); in 2013: 
103 (12,1%) patients. The predominant species, detected during period of inves-
tigation was Candida albicans (C.a.), which was isolated in 21 (44,7%), 21 (42%) 
and 52 (50,5%) patients in 2011,2012 and 2013 accordingly. Candida parapsilosis 
(C.p.) was on second place and frequency of this fungus detecting increased: 1 
(2,1%); 12 (24%); 31 (30,1%) patients. Candida tropicalis (C.t.) was detected: in 5 
(10,6%); 6 (12%); 10 (9,7%) patients. Candida glabrata (C.g.): in 9 (19,1%); 3 (6%); 2 
(1,9%). Candida krusei (C.k.): in 6 (12,8%); 1 (2%); 1 (1%). Candida lusitaniae (C.l.): 
in 2 (4,3%); 2 (4%); 3 (2,9%). Fluconazole susceptibility was: for C.a.: 100%; 89%; 
97%; C.t. 82%; 94%, 92%, C.g 18%; 46%; 0% in 2011, 2012 and 2013 accordingly; 
for C.p.: in 2012; 29%: in 2013: 23%. Changing of C. spp species distribution led 
to increasing of expenditure for antifungal drugs in ICU: 52% of expenditure for 
antimicrobial drugs in 2011; 72% in 2012; 78% in 2013. Echinocandines determined 
44%; 65% and 70% of ICU expenditure for antimicrobial drugs in 2011; 2012; 2013 
accordingly. cOnclusiOns: Our data coordinate with modern tendency in C. spp 
changing in ICUs. Increasing of C. spp proportion, resistant to fluconazole requires 
more frequent echinocandines use, that leads to rise of hospital expenditure.
PHP71
imPact of tHe early benefit assessment on a PHarmaceutical’s real 
consumPtion in germany
Kotowa W.1, Häussler B.2, Reindl S.1, Höer A.2
1IGES Institut GmbH, Nuremberg, Germany, 2IGES Institut GmbH, Berlin, Germany
Objectives: The Act on the Reform of the Market for Medicinal Products (“AMNOG”) 
introduced an early benefit assessment (EBA) of pharmaceuticals in Germany in 
2011. Since the impact of the results of the EBA on a pharmaceutical’s consumption 
is unclear, those effects were quantitatively analyzed. MethOds: All pharmaceuti-
cals which were assessed by an EBA in 2011 or 2012 and were still available in 2012 
and 2013, and gliptins launched before 2011 with an EBA in 2013 were considered. A 
pharmaceutical’s real consumption (measured by defined daily doses) in 2012 and 
2013 was compared to the expected consumption (EC) based on the highest possible 
number of patients defined by the Federal Joint Committee according to a pharma-
ceutical’s label. For the EC only subpopulations with an acknowledged additional 
benefit (AB) were taken into account. Results are presented in terms of „shares“ (= 
real consumption / EC). Results: Pharmaceuticals with a low share (< 10%) were 
cabazitaxel (0.22% in 2012), saxagliptin, protease inhibitors against chronic hepatitis 
C, eribulin, vandetanib and rilpivirin. Sitagliptin, ticagrelor, antineoplastic agents 
and tafamidis achieved a midsize share (10-50%). Ivacaftor, abiraterone, emtricita-
bin/rilpivirin/tenofovir, apixaban, fingolimod and axitinib reached shares of > 50% 
and up to 398%, respectively (fingolimod in 2013). There was no correlation between 
the extent of AB and a pharmaceutical‘s share. For most pharmaceuticals consump-
tion was higher in 2013 than 2012. cOnclusiOns: The shares of pharmaceuticals 
considered in this analysis vary between 0.22% and 398%. No correlation between 
share and extent of AB could be identified. It is assumed that label restrictions 
regarding the use of a pharmaceutical, competing alternatives in the same thera-
peutic indication, a pharmaceutical’s life-cycle or overestimation of the EC influence 
a pharmaceutical’s share. Shares > 100% indicate that also subpopulations without 
an acknowledged AB receive treatment with the respective pharmaceutical. Further 
research is needed to confirm these assumptions.
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up evenly at n= 3 each. cOnclusiOns: Pharmaceutical manufacturers are using 
innovative patient access schemes to gain access in emerging markets and are 
doing so by finding ways to drive down overall patient spend. While we were able to 
archetype innovative patient access schemes into three categories, it is important 
to note that many schemes incorporate elements from across the categories identi-
fied. Finally, when designing a scheme, pharmaceutical companies must take into 
account a host of factors including country level dynamics, company assets and 
strategy, and particulars of scheme design.
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Objectives: To define the possible ways of participation of patients in the deci-
sion-making processes in Slovakia. To analyze the current status of patients in 
the reimbursement process in Slovakia and to define barriers to the participa-
tion. MethOds: To identify the relevant literature, a survey was carried out using 
a search engine to the literature in PubMed 2000-2013. The survey was carried out 
using the following key words: “Patient participation”, “Patient choice”, in combina-
tion with the terms “Priority Setting”, “Innovation” or “Pharmaceutical Innovation”. 
Materials with those keywords were found, as well as through a Web browser. We 
performed analysis of the Slovak legislation, which regulates the status of patients 
in the reimbursement process and the comparison of this with other legislative 
standards, governing the status of citizens in public processes. There has also been 
evaluated legislative consultation process, which took place during the years 2010 
and 2011. Results: Actually the patients can (as the whole public) only view all 
documents relevant to reimbursement, since they are not a “registered” partici-
pant of the process. They are 3 possibilities to comment the process according to 
relevant legislation: send a writing comment to the MoH, draw up a petition, file a 
complaint. In the period 2010 – 2011, before the legislation change, the MoH received 
318 comments, from that 140 were from public. cOnclusiOns: The whole process 
is totally transparent and visible via internet site of MoH. The status of patients (e.g. 
patient representatives) in the process declined since the last change of legislation 
from 1.12.2011. Due to the introduction of WTP threshold for ICER/QALY is also the 
introduction of innovative drugs more restrictive as before, what makes the pos-
sibilities of patient participation in reimbursement process even more important.
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Objectives: We evaluated the data of license registry of Ukraine on 01.01.2014. 
Extemporaneous medicines are presented in 426 pharmacies, about 3% of the total 
number in Ukraine. The range of extemporaneous formulations in Ukraine is sig-
nificant, it is complemented by modern specifications physicians. MethOds: We 
analyzed the 1570 prescriptions on extemporaneous dosage forms of various doc-
tors in few Lviv pharmacies during 2013-2014. Results: We found that 53 names 
of substances used active substances and excipients. That should be noted that 
different formulations are made: medicine, tinctures, solutions, suspensions, drops, 
ointments, pastes, suppositories, powders. Among the most commonly prescribed 
by doctors’ prescriptions are liquid dosage forms, topical solution (solution furacillin 
0.02% - 500.0; rivanol 0.05%, 0.1% - 500.0; hydrogen peroxide 3% - 500 0, a solution 
of methylene blue 1% - 10.0), solutions for electrophoresis, nasal drops (solution 
collargolum 3% - 10.0 and protargolum 2% - 10.0), thymi water, soothing medicine 
quater, Pavlova, Ravkin. These pharmacies offer 26 solutions to supply hospitals. 
Also popular are antiflu powder (antigrypin) and vitamins, care products for face 
and body. Among soft medicines dominate ointment for wound healing (Lesyuk 
ointment, kalanhoie ointment) and for the treatment of sinusitis, Unna paste (for 
healing venous wounds), suppositories for hemorrhoid treatment (by prof. Maslyak) 
and antifungals (solution Kastelyani and various ointment). Currently, there are 
difficulties in ensuring substances, including missing: dibazol, diphenhydramine, 
collodion 4% lithium chloride, paracetamol, pepsin, yellow mercury, sulfur purified, 
diluted hydrochloric acid 8.4%, zinc sulfate, extract althey root, aminophylline, 1% 
citral alcohol solution. cOnclusiOns: Extemporaneous medicines are economi-
cally available, the average costs of solutions are 4-12 UAH (1 Euro= 16.0UAH), eye 
drops- 6-18 UAH, ointments - 5 - 15 UAH, which is 40-85% less than the manufactory 
drugs. That’s cost-effective therapy and provide individualized drug treatment for 
children, elderly, and chronically patients in Ukraine.
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Objectives: In 2014, the Irish Department of Health and Children (DoHC) published 
a policy document outlining the introduction of Universal healthcare by 2019. The 
impetus for adopting Universal healthcare is multi-faceted; the main driver being 
the current two-tier, private/public delivery system limits access to care for sub-
groups of the population. Inequality in access to care and clinical outcomes has been 
extensively published in Ireland; the implementation of Universal health care will 
aid in reducing this inequality as well as stabilise variation in resource use across 
socio-economic groups providing more efficient and equitable delivery of health 
care. The aim of this review was to catalogue what basic care is offered at the popula-
tion level across Universal delivery models in Europe and document disease-specific 
resource use and health outcomes as well as organisation around reimbursement 
structures for purposes of informing policy in Ireland. MethOds: EU-27 countries 
were classified by health care delivery systems according to data available from 
HealtH care use & Policy stuDies – equity and access
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Objectives: To describe and to compare the Colombian multidimensional poverty 
index (MPI) ’s trends against Gini coefficient (GC) and inequities in maternal mor-
tality and neonatal mortality since 1997 to 2011. MethOds: An ecological study 
was performed. MPI and Gini coefficient were obtained from National Statistics 
Department´s (DANE) databases. The Maternal Mortality Rate and Neonatal 
Mortality Rate were estimated and standardized by age and sex respectively. The 
Attributable Fraction (AF) was estimated as the inequity indicator for these two vari-
ables estimating the excess of risk by geographical exposure. We estimate the trend 
and behavior among MPI’s Colombian version and health inequities and disparities 
indicators over time from 1997 until 2011. Results: A substantial change was evi-
dent in the MPI 51% decrease (1997-2011) and 40%, (2003-2011) decreasing from 0.6 
to 0.3 (2003-2011), whilst Maternal Mortality attributable Fraction (MMAF) showed 
a 3% increase, rising from 83.4% to 86.2% (2000-2008), and a slight reduction for 
Neonatal Mortality attributable fraction (NMAF) 1.6%, (2000-2008) decreasing from 
88.9% to 88.4%. At the same time. GC evidenced a 1% decrease between 2000-2011 
decreasing from 0.57 to 0.54. cOnclusiOns: The established MPI for Colombia in 
the last decade had a descending trend and did not resemble the stationary behavior 
of the major inequity indicators calculated for the country in the same time span. 
Consequently, there was an undervalued perception over the issues where affected 
population were not target of requested interventions. It is therefore important to 
question the validity of measures used to quantify the poverty (MPI’s Colombian 
version) in order to reconsider the strategies of interventions where health inequity 
is an important referent to create control and intervention measures.
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Quality and risk management together, are prerequisites of patient safety which 
forms the basis of health care quality management activity. Objectives: To explore 
the prevailing organizational climate-in terms of clinical governance’ factors 
“Climate of blame and Punishment” and “A planned and integrated QI program and 
proactive risk management”, in Greek hospitals and to compare nurses’ perceptions 
with those of the rest health professionals on the particular factors. MethOds: It 
is a cross-sectional study, including a representative sample of all specialties of 
employees working in a public and a private Greek hospital. The validated Clinical 
Governance Climate Questionnaire (CGCQ) was filled by Nn= 261 nurses and Noth 
prof= 198 other professionals (response rate: 79%). A lower score signifies greater 
satisfaction in a particular concept. Data mining took place from May to August 
2012. Data analysis was performed with the SPSS 19.0 and included factor analysis, 
t-test, X2test and regression analysis The two-tailed significance level was set ≤ 
0.05. Results: The results for the factors “Climate of blame and Punishment” and “A 
planned and integrated QI program and proactive risk management”, demonstrated 
a slightly positive trend (Means: 2.73 and 2.28 respectively) in the total population. 
Nurses, appear to perceive more negatively the climate related to: i) protected time 
for Quality Improvement initiatives (p< 0.05), ii) systematic assessment of clinical 
risks (p< 0.001), iii) sharing of a common vision (p< 0.05), iv) dissemination of Risk 
prevention policies (p< 0.001), v) proactive risk management (p< 0.05), vi) systematic 
evaluation of Human Resources development needs (p< 0.001), vii) equal employee’s 
valuation regardless of professional background (p< 0.05). cOnclusiOns: The views 
of nurses are essential, as they are important and direct factors of care provision. 
The assessment of climate produces conclusions which if exploited properly, can 
mark the beginning and support the effort of continuous improvement of patient 
safety.
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Objectives: Emerging markets are a major priority for pharmaceutical manufac-
turers, and continue to grow as areas of interest for many firms. However, coverage 
from 3rd party payers, whether public or private, is often limited, and as a result 
the patient is the primary payer. Pharmaceutical companies must devise innovative 
strategies in order to provide access to patients while driving sales. In this study, we 
aimed to assess pharmaceutical company strategies to address patient affordability 
in emerging markets. MethOds: We undertook a secondary research horizon scan 
utilizing public resources to examine a variety of strategies, including innovative 
patient access schemes across emerging markets. We then filtered a total of n= 14 
schemes in emerging markets into several categories in order to create archetypes 
and to identify common themes and trends. Examples from a number of countries 
and regions were considered, including Brazil, China, India, sub-Saharan Africa, 
and others. Results: We categorized n= 14 patient access schemes into three main 
categories/archetypes: Licensing and Technology Transfer, Differential Pricing and 
Cost Offset Programs, and Value Added Services based on the primary objectives and 
characteristics of each scheme. A majority of programs fell under the Differential 
Pricing and Cost Offset programs (n= 8), with the other two categories splitting 
